Provectus Pharmaceuticals Inc. (PVCT.OB) is a company that specializes in oncology and dermatology therapies that are safer, more effective, less invasive, and more economical than conventional therapies. The company has also developed a number of intellectual properties and technologies in the areas of imaging, medical devices, and biotechnology.
Provectus is currently conducting Phase 2 clinical trials of their proprietary drugs — PV-10 as a therapy for metastatic melanoma and PH-10 as a topical treatment for moderate to severe psoriasis and atopic dermatitis. The company has received orphan drug designation from the FDA for PV-10.
Provectus announced that on September 10th, 2008, CEO Craig Dees, Ph.D. will present at the Wall Street Analyst Forum’s 19th Annual Analyst Conference. Mr. Dees will review the results of the Phase 1 clinical trial Provectus has completed in melanoma patients. In this study, individual tumors were injected with PV-10, and in many cases the tumors began dying within 7 days and lifted off the skin within 14 days.
In the Phase 2 trials of this drug, the first 20 of 80 patients have been treated with PV-10. The trial is being conducted by renowned oncology researcher, Professor John F. Thompson, M.D., who is director of the Sydney Melanoma Unit at the University of Sydney, Australia.
Let us hear your thoughts below: